Journal: Cancer discovery
This report describes a clinical study in relapsed multiple myeloma where a BCMA-directed T-cell engager was combined with an anti-CD38 monoclonal antibody.
- The dual immune approach produced very deep remissions and markedly lowered relapse rates compared with expectations for either strategy alone in this setting.
- These findings imply that simultaneous targeting of BCMA on myeloma cells and CD38 on plasma cells/immune subsets can substantially enhance disease control, raising the possibility that such combinations could be moved earlier in the treatment course.
- This strategy may alter current sequencing of therapies, including the timing or necessity of engineered T-cell approaches such as CAR T cells.